Study design (A) and patient disposition (B).

Slides:

Advertisements

Similar presentations

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Advertisements

Diabetes Prevention Program (DPP)

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Antihyperglycemic therapy in type 2 diabetes: general recommendations

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Management of Adult Patients with Hyperosmolar Hyperglycemic Syndrome

Patient disposition through 48 weeks in RA-BEYOND

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Trends in prevalence of diabetes in middle-aged women grouped according to BMI at the first survey of the ALSWH. ▪, healthy (n = 5,252); ♦, overweight.

A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

Study protocol. Study protocol. Fourteen patients had research renal biopsies, and 17 patients with macroalbuminuria had renal biopsies for clinical reasons.

Mean mesangial area (micron2) across normal controls (normal C), patients with type 2 diabetes and normoalbuminuria (normo), patients with type 2 diabetes.

The concept of immortal time bias is depicted schematically using the cohort study from the Taiwanese National Health Insurance data during 2000–2007:

FMD and PWV of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT. FMD measured at.

Saxagliptin improves glycemic control in younger and older individuals with type 2 diabetes. Saxagliptin improves glycemic control in younger and older.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

A single dose of liraglutide (Lira) (7. 5 μg/kg or 0

Odds of incident diabetes by OGTT insulin patterns according to subjects characterized by presence or absence of IGT or dichotomized at the median value.

Forefoot peak plantar pressure in diabetic patients without and with mild, moderate, and severe peripheral neuropathy. *Severe and moderate neuropathy.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

The effect of PAD and infection on outcome of cast treatment

Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Two-year changes in albumin-to-creatinine ratio across microalbuminuria at baseline. Two-year changes in albumin-to-creatinine ratio across microalbuminuria.

Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or.

A: Chemical structure of pterosin A

A1C (A) and serum glycated albumin (GA) (B) levels in 47 pregnant women (study 1) divided according to gestational period into group I (21–24 weeks; n.

RBC counts (A), hemoglobin (B), MCH (C), serum transferrin (Tf) saturation (D), and serum ferritin (E) in 47 pregnant women (study 1) divided according.

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Forest plot and pooled estimates of the effect of NAFLD on the risk of incident diabetes in 16 eligible studies, stratified by length of follow-up (FU)

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Study protocol. Study protocol. Eight subjects (seven men and one woman) with type 2 diabetes entered the study. The subjects discontinued their antidiabetic.

Effect of empagliflozin on efficacy parameters at week 18.

A total of 173 individuals were positive for GADA, and 16 of these were positive for a second antibody (11 were IA-2A positive, and 6 were ZnT8A positive).

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Glycemic control and body weight over 52 weeks.

Enrollment, outcomes, and pharmacokinetics.

Protocol for Management of Adult Patients with Diabetic Ketoacidosis

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Percent binding of cross-reactive antibodies from parallel studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Time course of HbA1c (A), FPG (B), body weight (C), SMPG (D), and lipase (E) from week 0 to week 26. Time course of HbA1c (A), FPG (B), body weight (C),

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Example of how quantitative variables displaying a nonhomogeneous risk in visual display were split in high- and low-risk categories. Example of how quantitative.

Distribution of daily frequency of BGM

A: Typical course of a normal sympathetic vasomotor response as recorded by continuous wave Doppler sonography. A: Typical course of a normal sympathetic.

Plots of average estimated and measured GFR vs

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

Incidences of transitions between glycemic states by 25-OHD level.

A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.

Antihyperglycemic therapy in adults with type 2 diabetes

Effects of metformin on GLP-1(7–36)amide degradation in vitro shown by GLP-1(7–36)amide concentrations (% variation from time 0) after a 30-min incubation.

Complex association between Hb level and GFR, sex, and AER

Upper panel: For performance of the 10-g monofilament test, the device is placed perpendicular to the skin, with pressure applied until the monofilament.

Patient disposition. *Patients who switched multiple times were not included in this analysis; **for patients switching treatment regimens, discontinuations.

Plasma metformin concentrations and bioavailability after administration of a single daily dose (study 1). Plasma metformin concentrations and bioavailability.

Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

A: Glucose levels during basal-bolus and SSI treatment.

Study design. aPatients initially receiving tenapanor 30 mg twice a day were allowed to down-titrate weekly (stepwise 30 → 20 → 15 → 10 → 3 mg twice a.

Presentation transcript:

Study design (A) and patient disposition (B). Study design (A) and patient disposition (B). (A) *Patients received 2,000 or 1,500 mg/day according to tolerability. (B) Patients discontinued at week 26 are also included as discontinued at week 52. aNumber of patients rescued at week 26 for severe, persistent hyperglycemia: dulaglutide 1.5 mg, 6 (2.2%); dulaglutide 0.75 mg, 6 (2.2%); and metformin, 7 (2.6%). bNumber of patients rescued at week 52 for severe, persistent hyperglycemia: dulaglutide 1.5 mg, 12 (4.5%); dulaglutide 0.75 mg, 8 (3.0%); and metformin, 14 (5.2%). BID, twice daily. Guillermo Umpierrez et al. Dia Care 2014;37:2168-2176 ©2014 by American Diabetes Association